CD38 is methylated in prostate cancer and regulates extracellular NAD+

Table 2 Higher CD38 is associated with a lower risk of recurrence after prostatectomy for clinically localized disease

Characteristic	Model 1	p value	Model 2	p value	Model 3	p value
Characteristic	Odds ratio (95% CI)	p value	Odds ratio (95% CI)	p value	Odds ratio (95% CI)	p value
Age at surgery (years)	0.81 (0.70–0.93)	0.003	0.81 (0.71–0.93)	0.003	0.81 (0.71–0.93)	0.003
Caucasian (yes/no)	0.09 (0.02–0.41)	0.002	0.10 (0.02–0.45)	0.003	0.11 (0.02–0.49)	0.004
High Gleason sum (yes/no)	1.44 (0.08–27.4)	0.819	1.80 (0.10–34.1)	0.715	1.41 (0.07–26.7)	0.831
S stage (yes/no)	2.09 (0.26–16.59)	0.487	2.06 (0.25–17.00)	0.502	2.31 (0.25–21.07)	0.457
Pre-op PSA (1 unit)	1.01 (0.99–1.03)	0.227	1.01 (0.99–1.03)	0.282	1.01 (0.99–1.03)	0.274
Surgical margins (+/−)	2.33 (1.65–3.30)	< 0.001	2.25 (1.60–3.17)	< 0.001	2.37 (1.68–3.36)	< 0.001
CD38 above med. cancer	0.69 (0.52–0.91)	0.007	XX	XX	XX	XX
CD38 above med. benign	XX	XX	0.91 (0.69–1.20)	0.505	XX	XX
CD38 above med. for both	XX	XX	XX	XX	0.65 (0.48–0.88)	0.006

Three conditional logistic regression models were run, each with the covariates mentioned above and CD38 as above the median in cancer cores (model 1), above the median in benign cores (model 2), and above the median in both (model 3). Odds ratios and 95% confidence intervals were extracted from each model

ISSN: 2049-3002